Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed stage IV or recurrent NSCLC of squamous or non-squamous histology that is not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy). * No prior treatment with systemic anti-cancer therapy for Stage IV disease. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to1. * Measurable disease by computed tomography or magnetic resonance imaging per RECIST v1.1. * Documentation of program death ligand-1 (PD-L1) status of 0 to 49% by IHC performed by the central laboratory prior to randomization. * Other protocol inclusion criteria may apply Exclusion Criteria: * Known epidermal growth factor receptor (EGFR) mutations sensitive to available targeted inhibitor therapy. * Known ALK or ROS1 rearrangements sensitive to available targeted inhibitor therapy. * Untreated central nervous system (CNS) metastases. * Unevaluable PD-L1 status or PD-L1 status of ≥ 50% by IHC performed by a central laboratory. * Carcinomatous meningitis. * Active, known or suspected autoimmune disease. * Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, IDO1 targeted agent, or any other antibody or drug targeting T cell co-stimulation or checkpoint pathways. * History of allergy or hypersensitivity to platinum-containing compounds or study drug components. * Physical and laboratory test findings outside the protocol-defined range. * Other protocol exclusion criteria may apply.